About Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors studied for obesity and metabolic syndrome with the largest weight-loss signals in clinical trials to date.
Research dose ranges
- Dose: 1000–12000 mcg per administration
- Frequency: 1× per day
- Route: subcutaneous
- Half-life: ~144 hours
- Cycle: 48 weeks on / 0 off
Phase II studied doses of 1, 2, 4, 8, and 12 mg weekly with a titration scheme similar to other GLP-1 class agents. As retatrutide is still investigational, doses outside of clinical trials are not established. Dose values are in mcg for consistency with the database schema (1000–12000 mcg = 1–12 mg).
Storage
As an investigational compound, retatrutide is not commercially available. Research samples should be stored per manufacturer specification, typically at 2–8°C.